Compare Equitable Holdings Inc. Common Stock (EQH) vs Heron Therapeutics Inc (HRTX) Price & Performance

Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.

EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.

HRTX trades at $0.3906, down 6.02% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $20.20 million on $154.90 million revenue in 2025, with a negative net income margin of -22.52%. Recent Q2 2026 earnings missed expectations, posting a loss of $0.03 per share versus an expected loss of $0.005. Analyst consensus remains strongly positive with 17 buy ratings out of 19 total.

The outlook is mixed; strong analyst support and improving cash flow trends in 2026 suggest potential, but persistent losses and high valuation multiples like EV/EBITDA of 34.03 pose significant risks. Investment opportunity hinges on future profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.